60 related articles for article (PubMed ID: 38467639)
1. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum-containing chemotherapy. A Cochrane Rapid Review.
Narayan V; Kahlmeyer A; Dahm P; Skoetz N; Risk MC; Bongiorno C; Patel N; Hwang EC; Jung JH; Gartlehner G; Kunath F
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012838. PubMed ID: 30036453
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial.
Hsiehchen D; Beg MS; Kainthla R; Lohrey J; Kazmi SM; Khosama L; Maxwell MC; Kline H; Katz C; Hassan A; Kubota N; Siglinsky E; Pillai AK; Youssoufian H; Mockbee C; Culm K; Uhlik M; Benjamin L; Brekken RA; Ahn C; Singal AG; Zhu H; Hoshida Y; Yopp AC
Nat Commun; 2024 Mar; 15(1):2178. PubMed ID: 38467639
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
9. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Van Dao T; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Marcovitz M; Makowsky M; He P; Kurland JF; Negro A; Sangro B
NEJM Evid; 2022 Aug; 1(8):EVIDoa2100070. PubMed ID: 38319892
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer.
Herzog BH; Baer JM; Borcherding N; Kingston NL; Belle JI; Knolhoff BL; Hogg GD; Ahmad F; Kang LI; Petrone J; Lin CY; Govindan R; DeNardo DG
Sci Transl Med; 2023 Jun; 15(699):eadh8005. PubMed ID: 37285399
[TBL] [Abstract][Full Text] [Related]
11. Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.
Uhlik M; Pointing D; Iyer S; Ausec L; Štajdohar M; Cvitkovič R; Žganec M; Culm K; Santos VC; Pytowski B; Malafa M; Liu H; Krieg AM; Lee J; Rosengarten R; Benjamin L
Front Oncol; 2023; 13():1158345. PubMed ID: 37251949
[TBL] [Abstract][Full Text] [Related]
12. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy.
Zhang E; Ding C; Li S; Zhou X; Aikemu B; Fan X; Sun J; Zheng M; Yang X
Biomark Res; 2023 Mar; 11(1):28. PubMed ID: 36890557
[TBL] [Abstract][Full Text] [Related]
13. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX; Abbas AR; de Galarreta MR; Guan Y; Lu S; Koeppen H; Zhang W; Hsu CH; He AR; Ryoo BY; Yau T; Kaseb AO; Burgoyne AM; Dayyani F; Spahn J; Verret W; Finn RS; Toh HC; Lujambio A; Wang Y
Nat Med; 2022 Aug; 28(8):1599-1611. PubMed ID: 35739268
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Fu S; Corr BR; Culm-Merdek K; Mockbee C; Youssoufian H; Stagg R; Naumann RW; Wenham RM; Rosengarten RD; Benjamin L; Hamilton EP; Moore KN
J Clin Oncol; 2022 Aug; 40(23):2568-2577. PubMed ID: 35439029
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
Verset G; Borbath I; Karwal M; Verslype C; Van Vlierberghe H; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline J; Cattan S; Kudo M; Cheng AL; Ogasawara S; Daniele B; Chan SL; Knox JJ; Qin S; Siegel AB; Chisamore M; Hatogai K; Wang A; Finn RS; Zhu AX
Clin Cancer Res; 2022 Jun; 28(12):2547-2554. PubMed ID: 35421228
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
